Search the Newsreel

Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 1,889,366 common shares of Fennec Pharmaceuticals Inc. (FENC), representing a 5.4% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing. The ownership is held through a private …

Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) significantly surpassed revenue and EPS expectations in its second-quarter report. Following these strong results, analysts have upgraded their forecasts for 2026, increasing revenue predictions to US$72.9m and EPS to US$0.32, and raising the price target by 13% to US$17.67. The …

Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views

Analysts have raised their fair value estimate for Fennec Pharmaceuticals (FENC) from US$15.33 to US$17.67 per share, attributing this increase to stronger-than-expected PEDMARK revenue, its expanded use across various tumor types, and improved operating leverage. Several firms, including B. Riley, Wedbush, and H.C. Wainwright, …

Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors

Rosalind Advisors Inc. and related parties have reported a 9.6% beneficial ownership stake in Fennec Pharmaceuticals Inc. (FENC), holding 3,321,333 common shares. This ownership includes shares held by Rosalind Master Fund L.P., and involves shared voting and dispositive power among Rosalind Advisors, Steven Salamon, …

B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC)

Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade)

Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question

Fennec Pharmaceuticals (FENC) stock surged 17% after its Q2 2026 earnings report showed unexpected profitability, with net income reaching US$2.0 million on US$17.9 million revenue. This shift from a prior-year loss has fueled a bullish growth story centered on its product PEDMARK, backed by …

Fennec Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $16.17, Implies 48% Upside

Analysts have increased the average 12-month price target for Fennec Pharmaceuticals Inc. (FENC) stock to $16.17, up from $15.67, with individual forecasts ranging from $15 to $18 per share. This new target suggests a potential upside of approximately 48% from its August 10 closing …

Fennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record High

Fennec Pharmaceuticals announced a significant 78% year-over-year increase in Pedmark net product sales for Q2 2026, reaching $17.1 million, and reported a record non-GAAP adjusted EBITDA of $2.8 million. This marks the company's seventh consecutive quarter of growth, driven by expanding commercial efforts and …

Adherex Technologies Q2 2026 Earnings Call Transcript

Adherex Technologies (FENC) reported strong Q2 2026 earnings, with PEDMARK net product sales increasing by 78% year-over-year to $17.1 million and achieving its seventh consecutive quarter of growth. The company saw significant commercial momentum driven by an expanded sales force, successful disease awareness campaigns, …

Fennec Pharmaceuticals Releases Q2 2026 Financial Results

Fennec Pharmaceuticals Inc. reported strong Q2 2026 financial results, with diluted earnings of $0.05 per share, significantly beating the $0.01 consensus. The company's revenue reached $17.9M, an 85% increase year-over-year, and net income was $2.0M, a substantial improvement from a loss in the prior …

Adherex Technologies (NASDAQ:FENC) Announces Earnings Results, Beats Estimates By $0.03 EPS

Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates

Fennec Pharmaceuticals (NASDAQ:FENC) saw an 8% pre-market surge after reporting better-than-expected Q2 earnings and revenue, driven by a 78% increase in PEDMARK sales. The company achieved adjusted earnings of $0.05 per share and revenue of $17.87 million, surpassing analyst estimates. This performance also marked …

FENNEC PHARMACEUTICALS ($FENC) Releases Q2 2026 Earnings

Paras Defence Space Tech Q1 Results: Board Approves Q1FY27 Filing

FENC Q1 2026 Earnings: EPS Beats Estimates by 217.7%, Stock Jumps 6.8% - Earnings Revision Report

Paras Defence approves sale of Krasny stake to Krasny Defence Technologies

Paras Defence Q1 results: Net profit grows 40% YoY; board fixes record date for dividend payout

Responsive Playbooks and the FENC Inflection

This article provides an in-depth AI-driven analysis of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), highlighting divergent sentiment readings and identifying resistance and support levels. It outlines specific institutional trading strategies, including long, breakout, and short setups, with defined entry, target, and stop-loss zones. The analysis …

Adherex Technologies (FENC) Projected to Release Quarterly Earnings on Thursday

Fennec Pharmaceuticals to report Q2 2026 earnin...

Fennec Pharmaceuticals Inc. will release its second-quarter 2026 financial results on August 11, 2026, before U.S. markets open. The company, which specializes in treatments to reduce chemotherapy-induced hearing loss, will host a conference call and webcast to discuss its financial and business performance. This …

Stocks in play: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. (T.FRX) is set to release its second-quarter 2026 financial results before the U.S. financial markets open on Tuesday, August 11. Currently, Fennec Pharmaceuticals Inc. shares are trading unchanged at $13.85. This announcement provides key information for investors tracking the company's performance.

Fennec sets Aug. 11 call to discuss second-quarter results

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) announced it will release its second-quarter 2026 financial results before the U.S. market opens on Tuesday, August 11, 2026. A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the financial and business results. …

Fennec Pharmaceuticals (FENC) Former Director Rosty Raykov Sells 10,000 Shares

Rosty Raykov, a former director of Fennec Pharmaceuticals (FENC), sold 10,000 shares of the company's stock on August 3, 2026, for approximately $95,800. This sale is part of a broader pattern of insider selling, with 18 insider sells and zero buys over the past …

Fennec Pharmaceuticals (FENC) Gains 1.67% as Shares Advance to $9.75 - BPI Bull Confirmed

Fennec Pharmaceuticals (FENC) CCO receives 168 vested shares

Fennec Pharmaceuticals' Chief Commercial Officer, Terry L. Evans, acquired 168 Common Shares on July 31, 2026, through the vesting of restricted shares originally awarded in March 2025. This transaction increases his direct holdings to 21,351 Common Shares. The shares were acquired at a price …

Fennec Pharmaceuticals (FENC) CEO gets 1,159-share award

Fennec Pharmaceuticals CEO Jeffrey S. Hackman received an award of 1,159 common shares on July 31, 2026, stemming from the release of restrictions on

Fennec Pharmaceuticals (FENC) CMO gains 168 shares as award vests

Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sargis Sayad, acquired 168 common shares on July 31, 2026, as restrictions were released on an award from March 28, 2025. This transaction, valued at $0.00 per share, increased his direct ownership to 21,351 common shares. The acquisition …

Defence Holdings Plc Revenue Breakdown – LSE:ALRT

Fennec Pharmaceuticals Inc (FENC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Fennec Pharmaceuticals Inc (FENC), highlighting its current valuation score and P/E ratio. The company's valuation score is 9.27, ranking 36th out of 155 in the Pharmaceuticals industry. It notes that key P/B, P/S, and P/CF data have …

ALRT: No revenue, strategic pivot to defence AI, first MoD contract post-year-end, strong capital base

Fennec Pharmaceuticals Inc (FENC) Institutional Confidence

Fennec Pharmaceuticals Inc (FENC) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 53.51%, a 16.42% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 0.51% of outstanding …

Fennec Pharmaceuticals Inc (FENC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Fennec Pharmaceuticals Inc (FENC), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, including hedge funds and corporations, and tracks the historical changes in institutional shareholding and individual shareholder activity. The article …